Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Nexstim Plc, a medical technology enterprise, specializes in the creation and global distribution of non-invasive brain stimulation technologies, with operations spanning Finland, Europe, North America, and other international markets. Central to its offerings is the proprietary SmartFocus technology, featuring 3D navigation, which underpins its navigated transcranial magnetic stimulation (TMS) approach utilized for both therapeutic interventions and diagnostic assessments. The company provides two distinct systems: the NBT system, a navigated brain therapy solution designed for addressing major depression and chronic neuropathic pain, and the NBS system, a navigated brain stimulation device engineered for precise pre-surgical mapping of the brain's speech and motor cortices. Nexstim predominantly sells its NBS systems to academic institutions and teaching hospitals. Established in 2000, Nexstim Plc's corporate headquarters are located in Helsinki, Finland.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITD.
Target Price
The average target price of NXTMH.HE is 11.0 and suggests 11.7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommend